B
제놀루션
225220KOSDAQ58.5 / 100
Reference Date: 2026-10-23
Financial Score20.0 / 40
News Sentiment12.5 / 25
Momentum16.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 12.8% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Genolux operates in the molecular diagnostic equipment and RNAi research sectors, offering automated nucleic acid extraction devices and RNA synthesis services. The company has developed the world's first RNAi-based treatment for foulbrood disease in bees and obtained product approval, while expanding its RNAi-based agricultural pest control technologies.
Number of Employees
76people
Average Salary
53.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.46Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
-16.98Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
0.44Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20251.0 / 10 points
Revenue Growth Rate
1.0 / 3
Avg ▲2.4% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼11.8% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -10.6% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position5.0Point
52w mid range (48%)
Current 1,618Won52-week high 2,24052-week low 1,030
1-month return5.0Point
1m +12.83% (rising)
Volume trend6.0Point
Volume increasing
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-10-16
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-16
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-02